Candida and candidiasis in HIV-infected patients: Where commensalism, opportunistic behavior and frank pathogenicity lose their borders

AIDS

Volumn 26, Issue 12, 2012, Pages 1457-1472

  Cassone, Antonio ^a   Cauda, Roberto ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

AIDS; Candida albicans; oropharyngeal candidiasis; pathogenesis; therapy; vaccines

Indexed keywords

ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ASPARTIC PROTEINASE; BETA GLUCAN; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENT; DECTIN 1; FLUCONAZOLE; GALECTIN 3; GAMMA INTERFERON; GLYCOPROTEIN GP 160; HISTATIN 5; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; MANNOSE RECEPTOR; SUBUNIT VACCINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; UVOMORULIN;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMMENSALISM; DISEASE COURSE; ENZYME RELEASE; ESOPHAGUS CANDIDIASIS; FUNGAL VIRULENCE; FUNGUS GROWTH; FUNGUS HYPHAE; HELPER CELL; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VIVO STUDY; INFECTION CONTROL; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; OROPHARYNX CANDIDIASIS; PATHOGENICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TH17 CELL; VAGINA CANDIDIASIS;

CANDIDA ALBICANS; CANDIDIASIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ESOPHAGEAL DISEASES; HIV; HIV INFECTIONS; HUMANS; PHARYNGEAL DISEASES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84864289915     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283536ba8     Document Type: Review

References (133)

1. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984; 311:354-358.
2. Tavitian A, Raufman JP, Rosenthal LE. Oral candidiasis as a marker for esophageal candidiasis in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104:54-55.
3. Guihot A, Bourgarit A, Carcelain G, Autran B. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol 2011; 32:131-137.
4. Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H, Schneider L, et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 2011; 117:5142-5151.
5. Pakker NG, Roos MT, van Leeuwen R, de Jong MD, Koot M, Reiss P, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:318-326.
6. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
7. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA 1998; 280:72-77.
8. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, et al. Epidemiology of oral candidiasis in HIVinfected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97:339-346.
9. Huppmann AR, Orenstein JM. Opportunistic disorders of the gastrointestinal tract in the age of highly active antiretroviral therapy. Hum Pathol 2010; 41:1777-1787.
10. Vazquez JA. Invasive oesophageal candidiasis. Drugs 2003; 63:921-932.
11. Thompson GR 3rd, Patel PK, Kirkpatrick WR, Westbrook SD, Berg D, Erlandsen J, et al. Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:488-495.
12. Traeder C, Kowoll S, Arastéh K. Candida infection in HIV positive patients 1985-2007. Mycoses 2008; 51 (Suppl 2): 58-61.
13. Fichtenbaum CJ, Powderly WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 1998; 26:556-565.
14. Nkuize M, De Wit S, Muls V, Arvanitakis M, Buset M. Upper gastrointestinal endoscopic findings in the era of highly active antiretroviral therapy. HIV Med 2010; 11:412-417.
15. Ohmit SE, Sobel JD, Schuman P, Duerr A, Mayer K, Rompalo A, et al., HIV Epidemiology Research Study (HERS) Group. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003; 188:118-127.
16. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 174:821-827.
17. Revankar SG, Sanche SE, Dib OP, Caceres M, Patterson TF. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. AIDS 1998; 12:2511-2513.
18. Revankar SG, Dib OP, Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26:960-963.
19. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, et al. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med 1998; 105: 7-11.
20. Fidel PL. Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis. Adv Dent Res 2011; 23:45-49.
21. Challacombe SJ, Naglik Jr. The effects of HIV infection on oral mucosal immunity. Adv Dent Res 2006; 19:29-35.
22. Fidel PL Jr. Distinct protective host defenses against oral and vaginal candidiasis. Med Mycol 2002; 40:359-375.
23. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006; 20:485-506.
24. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535.
25. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178:203-211.
26. Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 2012; 54:424-433.
27. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332: 65-68.
28. Gutiérrez J, Morales P, González MA, Quindós G. Candida dubliniensis, a new fungal pathogen. J Basic Microbiol 2002; 42:207-227.
29. Moran GP, Coleman DC, Sullivan DJ. Candida albicans versus Candida dubliniensis: why is C. albicans more pathogenic? Int J Microbiol 2012. doi: 10.1155.2012.205921.
30. Biswas S, Van Dijck P, Datta A. Environmental sensing and signal transduction pathways regulating morphopathogenic determinants of Candida albicans. Microbiol Mol Biol Rev 2007; 71:348-376.
31. Hall RA, Turner KJ, Chaloupka J, Cottier F, De Sordi L, Sanglard D, et al. The quorum sensing molecule farnesol/homoserine lactone and dodecanol operate via distinct modes of action in Candida albicans eukaryot. Cell 2011; 10:1034-1042.
32. Soll DR. Why does Candida albicans switch?. FEMS Yeast Res 2009; 9:973-989.
33. Bennett RJ, Uhl MA, Miller MG, Johnson AD. Identification and characterization of a Candida albicans mating pheromone. Mol Cell Biol 2003; 23:8189-8201.
34. Simonetti n, Strippoli V, Cassone A. Yeast-mycelial transition induced by N-acetyl-D-glucosamine in Candida albicans. Nature 1974; 250:344-346.
35. Huang G, Yi S, Sahni N, Daniels KJ, Srikantha T, Soll DR. N-Acetylglucosamine induces white to opaque switching: a mating prerequisite in Candida albicans. PLoS Pathog 2010; 6:3. doi: 10.1371.
36. Romani L. Immunity to fungal infections. Nat Rev Immunol 201; 11:275-288.
37. Cheng SC, Joosten LA, Kullberg BJ, Netea MG. The interplay between Candida albicans and the mammalian innate host defense. Infect Immun 2012 80 :1304-1313.
38. Zhu W, Filler SG. Interactions of Candida albicans with epithelial cells. Cell Microbiol 2010; 12:273-282.
39. Weindl G, Wagener J, Schaller M. Epithelial cells and innate antifungal defense. J Dent Res 2010; 89:666-675.
40. Naglik JR, Moyes DL, Wächtler B, Hube B. Candida albicans interactions with epithelial cells and mucosal immunity. Microbes Infect 2011; 13:963-976.
41. Ganguly S, Mitchell AP. Mucosal biofilms of Candida albicans. Curr Opin Microbiol 2011; 14:380-385.
42. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003; 67:400-428.
43. De Bernardis F, Sullivan PA, Cassone A. Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol 2001; 39:303-313.
44. Monod M, Borg-von ZM. Secreted aspartic proteases as virulence factors of Candida species. Biol Chem 2002; 383: 1087-1093.
45. Correia A, Lermann U, Teixeira L, Cerca F, Botelho S, da Costa RM, et al. Limited role of secreted aspartyl proteinases Sap1 to Sap6 in Candida albicans virulence and host immune response in murine hematogenously disseminated candidiasis. Infect Immun 2010; 78:4839-4849.
46. Naglik JR, Moyes D, Makwana J, Kanzaria P, Tsichlaki E, Weindl G, et al. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 2008; 154:3266-3280.
47. Naglik JR, Rodgers CA, Shirlaw PJ, Dobbie JL, Fernandes-Naglik LL, Greenspan D, et al. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J Infect Dis 2003; 188:469-479.
48. Frank CF, Hostetter MK. Cleavage of E-cadherin: a mechanism for disruption of the intestinal epithelial barrier by Candida albicans. Transl Res 2007; 149:211-222.
49. Quimby K, Lilly E, Zacharek M, McNulty K, Leigh J, Vazquez J, et al. CD8 T cells and E-cadherin in host responses against oropharyngeal candidiasis. Oral Dis 2012; 18:153-161.
50. Villar CC, Kashleva H, Nobile CJ, Mitchell AP, Dongari-Bagtzoglou A. Mucosal tissue invasion by Candida albicans is associated with E-cadherin degradation, mediated by transcription factor Rim101p and protease Sap5p. Infect Immun 2007; 75:2126-2135.
51. Gropp K, Schild L, Schindler S, Hube B, Zipfel PF, Skerka C. The yeast Candida albicans evades human complement attack by secretion of aspartic proteases. Mol Immunol 2009; 47:465-475.
52. Pietrella D, Rachini A, Pandey N, Schild L, Netea M, Bistoni F, et al. The Inflammatory response induced by aspartic proteases of Candida albicans is independent of proteolytic activity. Infect Immun 2010; 78:4754-4762.
53. Chen YL, Brand A, Morrison EL, Silao FG, Bigol UG, Malbas FF Jr. Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. Eukaryot Cell 2011; 10:803-819.
54. Meiller TF, Hube B, Schild L, Shirtliff ME, Scheper MA, Winkler R, et al. A novel immune evasion strategy of Candida albicans: proteolytic cleavage of a salivary antimicrobial peptide. PLoS One 2009; 4:e5039.
55. Brandtzaeg P, Gabrielsen TO, Dale I, Mü ller F, Steinbakk M, Fagerhol MK. The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Adv Exp Med Biol 1995; 371:201-206.
56. Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, et al. Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun 1999; 67:2740-2745.
57. Moyes DL, Runglall M, Murciano C, Shen C, Nayar D, Thavaraj S, et al. A biphasic innate immune MAPK response discriminates between the yeast and hyphal forms of Candida albicans in epithelial cells. Cell Host Microbe 2010; 8:225-235.
58. Gow NA, van de Veerdonk FL, Brown AJ, Netea MG. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol 2011; 10:112-122.
59. Tomalka J, Ganesan S, Azodi E, Patel K, Majmudar P, Hall BA, et al. A novel role for the NLRC4 inflammasome in mucosal defenses against the fungal pathogen Candida albicans. PLoS Pathog 2011; 7:e1002379.
60. Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009; 206:299-311.
61. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of Th17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2:32-36.
62. De Luca A, Zelante T, D'Angelo C, Zagarella S, Fallarino F, Spreca A, et al. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol 2010; 3:361-373.
63. Pietrella D, Rachini A, Pines M, Pandey N, Mosci P, Bistoni F, et al. Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS One 2011; 6:e22770.
64. Fenoglio D, Poggi A, Catellani S, Battaglia F, Ferrera A, Seti M, et al. Vdelta1 T lymphocytes producing IFNg patients and IL-17 are expanded in HIV-infected and respond to Candida albicans. Blood 2009; 113:6611-6618.
65. + lymphocytes. J Immunol 1995; 154:5273-5281.
66. Arancia G, Molinari A, Crateri P, Stringaro A, Ramoni C, Dupuis ML, et al. Noninhibitory binding of human interleukin-2-activated natural killer cells to the germ tube forms of Candida albicans. Infect Immun 1995; 63:280-288.
67. Haas A, Zimmermann K, Graw F, Slack E, Rusert P, Ledergerber B, et al. Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut 2011; 60:1506-1519.
68. Cutler JE, Deepe GS, Klein D. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 2007; 5:13-28.
69. Cassone A. Fungal vaccines: real progress from real challenge. Lancet Infect Dis 2008; 8:114-124.
70. Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14:107-111.
71. Demberg T, Ettinger AC, Aladi S, McKinnon K, Kuddo T, Venzon D, et al. Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory. Vaccine 2011; 29:6017-6028.
72. + T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected longterm nonprogressors. J Virol 2011; 85:5880-5888.
73. Salgado M, Rallón NI, Rodés B, López M, Soriano V, Benito JM. Long-term nonprogressors display a greater number of Th17 cells than HIV-infected typical progressors. Clin Immunol 2011; 139:110-114.
74. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441:235-238.
75. Torosantucci A, Chiani P, Cassone A. Differential chemokine response of human monocytes to yeast and hyphal forms of Candida albicans and its relation to the beta-1,6 glucan of the fungal cell wall. J Leukoc Biol 2000; 68:923-932.
76. Torosantucci A, Chiani P, Ausiello CM, Mezzaroma I, Cassone A. Responsiveness of human polymorphonuclear cells (PMNL) to stimulation by a mannoprotein fraction (MP-F2) of Candida albicans :enhanced production of IL-6 and tumor necrosis factor-alpha(TNF-alpha) by MP-F2-stimulated PMNL from HIV-infected subjects. Clin Exp Immunol 1997; 107:451-457.
77. Cassone A, Chiani P, Quinti I, Torosantucci A. Possible participation of polymorphonuclear cells stimulated by microbial immunomodulators in the dysregulated cytokine patterns of AIDS patients. J Leukoc Biol 1997; 62:60-66.
78. Nisini R, Torosantucci A, Romagnoli G, Chiani P, Donati S, Gagliardi MC, et al. beta-Glucan of Candida albicans cell wall causes the subversion of human monocyte differentiation into dendritic cells. J Leukoc Biol 2007; 82:1136-1142.
79. Schaller M, Mailhammer R, Grassl G, Sander CA, Hube B, Korting HC. Infection of human oral epithelia with Candida species induces cytokine expression correlated to the degree of virulence. J Invest Dermatol 2002; 118:652-657.
80. Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, et al. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol 2006; 13:1111-1118.
81. Blauvelt A, Clerici M, Lucey DR, Steinberg SM, Yarchoan R, Walker R, et al. Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. J Immunol 1995; 154:3506-3515.
82. Qureshi MN, Barr CE, Hewlitt I, Boorstein R, Kong F, Bagasra O, et al. Detection of HIV in oral mucosal cells. Oral Dis 1997; 3 (Suppl 1):S73-S78.
83. Frohner IE, Bourgeois C, Yatsyk K, Majer O, Kuchler K. Candida albicans cell surface superoxide dismutases degrade host-derived reactive oxygen species to escape innate immune surveillance. Mol Microbiol 2009; 71:240-252.
84. Luo S, BlomAM, Rupp S, HiplerUC,Hube B, Skerka C, et al. The pH-regulated antigen 1 of Candida albicans binds the human complement inhibitorC4b-binding protein andmediates fungal complement evasion. J Biol Chem 2011; 286:8021-8029.
85. Mora-Montes HM, Netea MG, Ferwerda G, Lenardon MD, Brown GD, Mistry AR, et al. Recognition and blocking of innate immunity cells by Candida albicans chitin. Infect Immun 2011; 79:1961-1970.
86. de Boer AD, de Groot PW, Weindl G, Schaller M, Riedel D, Diez-Orejas R. The Candida albicans cell wall protein Rhd3/Pga29 is abundant in the yeast form and contributes to virulence. Yeast 2010; 27:611-624.
87. De Bernardis F, Chiani P, Ciccozzi M, Pellegrini G, Ceddia T, D'Offizzi G, et al. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect Immun 1996; 64:466-471.
88. Heilmann CJ, Sorgo AG, Siliakus AR, Dekker HL, Brul S, de Koster CG, et al. Hyphal induction in the human fungal pathogen Candida albicans reveals a characteristic wall protein profile. Microbiology 2011; 157:2297-2307.
89. Mane A, Gaikwad S, Bembalkar S, Risbud A. Increased expression of virulence attributes in oral Candida albicans isolates from human immunodeficiency virus-positive individuals. J Med Microbiol 2012; 61:285-290.
90. Ripeau JS, Fiorillo M, Aumont F, Belhumeur P, de Repentigny L. Evidence for differential expression of Candida albicans virulence genes during oral infection in intact and human immunodeficiency virus type 1-transgenic mice. J Infect Dis 2002; 185:1094-1102.
91. Vargas KG, Joly S. Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. J Clin Microbiol 2002; 40:341-350.
92. Gruber A, Lell CP, Speth C, Stoiber H, Lass-Flö rl C, Sonneborn A, et al. Human immunodeficiency virus type 1 Tat binds to Candida albicans, inducing hyphae but augmenting phagocytosis in vitro. Immunology 2001; 104:455-461.
93. Gruber A, Lukasser-Vogl E, Borg-von Zepelin M, Dierich MP, Würzner R. Human immunodeficiency virus type 1 GP160 and GP41 binding to Candida albicans selectively enhances Candidal virulence in vitro. J Infect Dis 1998; 177:1057-1063.
94. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo antiCandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180:448-453.
95. De Bernardis F, Tacconelli E, Mondello F, Cataldo A, Arancia S, Cauda R, et al. Antiretroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their antimycotic susceptibility. FEMS Immunol Med Microbiol 2004; 41:27-34.
96. Cassone A, Tacconelli E, De Bernardis F, Tumbarello M, Torosantucci A, Chiani P, et al. Antiretroviral therapy with protease inhibitors has an early, immune reconstitutionindependent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J Infect Dis 2002; 185:188-195; 97.
97. Cauda R, Tacconelli E, Tumbarello M, Morace G, De Bernardis F, Torosantucci A, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 1999; 21:20-25.
98. Gruber A, Speth C, Lukasser-Vogl E, Zangerle R, Borg-von Zepelin M, Dierich MP, Würzner R. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 1999; 41:227-234.
99. Monari C, Pericolini E, Bistoni G, Cenci E, Bistoni F, Vecchiarelli A. Influence of indinavir on virulence and growth of Cryptococcus neoformans. J Infect Dis 2005; 191:307-311.
100. Palmeira VF, Kneipp LF, Rozental S, Alviano CS, Santos AL. Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence. PLoS One 2008; 3:e3382.
101. Skimer-Adams T, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. Antiretroviral as antimalarial agents. J Infect Dis 2004; 190:1998-2000.
102. Braga-Silva LA, Santos AL. Aspartic protease inhibitors as potential anti-Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis. Curr Med Chem 2011; 18:2401-2419.
103. Luallen RJ, Fu H, Agrawal-Gamse C, Mboudjeka I, Huang W, Lee FH, et al. A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits GP120 interactions with 2G12 and DC-SIGN. J Virol 2009; 83:4861-4870.
104. Jung HJ, Park Y, Hahm KS, Lee DG. Biological activity of Tat (47-58) peptide on human pathogenic fungi. Biochem Biophys Res Commun 2006; 345:222-228.
105. Agrawal-Gamse C, Luallen RJ, Liu B, Fu H, Lee FH, Geng Y, et al. Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans. J Virol 2011; 85:470-480.
106. Lee J, Lee DH, Lee DG. Candidacidal effects of Rev (11-20) derived from HIV-1 Rev protein. Mol Cells 2009; 28:403-406.
107. Polonelli L, Pontón J, Elguezabal N, Moragues MD, Casoli C, Pilotti E, et al. Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS One 2008; 3:e2371.
108. Casoli C, Pilotti E, Perno CF, Balestra E, Polverini E, Cassone A, et al. A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication. AIDS 2006; 20:975-980.
109. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, Kauffman CA. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38:2495-2497.
110. Goldman M, Cloud GA, Wade KD, Reboli AC, Fichtenbaum CJ, Hafner R, et al. AIDS Clinical Trials Group Study Team 323; Mycoses Study Group Study Team 40. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005; 41:1473-1480.
111. Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, et al. Treatment of oral candidiasis in HIV infection. Oral Surg Oral Med Oral Pathol 1994; 78:211-215.
112. Hegener P, Troke PF, Fätkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12:2227-2238.
113. Schubert S, Barker KS, Znaidi S, Schneider S, Dierolf F, Dunkel N, et al. Regulation of efflux pump expression and drug resistance by the transcription factors MRR1, UPC2, AND CAP1 in Candida albicans. Antimicrob Agents Chemother 2011; 55:2212-2223.
114. Ferrari S, Sanguinetti M, Torelli R, Posteraro B, Sanglard D. Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata. PLoS One 2011; 6:e17589.
115. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
116. de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, et al. A randomized, double-blind, parallelgroup, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39:842-849.
117. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39:770-775.
118. Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D, et al. Posaconazole for the treatment of azolerefractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44: 607-614.
119. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of Candidal esophagitis. Clin Infect Dis 2001; 33:1529-1535.
120. Ostrowski-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010; 9: 719-727.
121. Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57:705-708.
122. Bein M, Schaller M, Korting HC. The secreted aspartic proteinases as a new target in the therapy of candidiasis. Curr Drug Targets 2002; 3:351-357.
123. Trabocchi A, Mannino C, Machetti F, De Bernardis F, Arancia S, Cauda R, et al. Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds. J Med Chem 2010; 53:2502-2509.
124. Chiani P, Bromuro C, Cassone A, Torosantucci A. Antibetaglucan antibodies in healthy human subjects. Vaccine 2009; 27:2513-2519.
125. Sandini S, La Valle R, Deaglio S, Malavasi F, Cassone A, De Bernardis F. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal antiCandidal vaccine. FEMS Immunol Med Microbiol 2011; 62:215-224.
126. Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y, Mignogna G, et al. Protection by antibeta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 2009; 4:e5392.
127. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005; 202:597-606.
128. Xin H, Dziadek S, Bundle DR, Cutler JE. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad SciUS A 2008; 105:13526-13531.
129. Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, et al. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal Candidiasis. J Infect Dis 2006; 194:256-260.
130. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5:e1000703.
131. De Bernardis F, Amacker M, Arancia S, Sandini S, Gremion C, Moser C, et al. A virosomal vaccine against Candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine (submitted).
132. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection : causes and consequences. J Pathol 2008; 214:231-241.
133. Zelante T, Iannilli RG, De Luca A, Arroyo J, Blanco N, Servillo G, et al. Sensing of the mammalian IL-17 regulates fungal adaptation and virulence. Nat Com 2012; DOI 10.1038/ncomms 1085.